|
1) Guron G, et al. An intact renin-angiotensin sys-tem is a prerequisite for normal renal develop-ment. Hypertension. 2000; 18: 123-37
|
|
|
|
2) (財)日本医薬情報センター. カンデサルタンシレキシル(ブロプレス)添付文書. In: 医療用医薬品集. 2007. p. 690-2
|
|
|
|
|
|
3) Saji H, et al. Losartan and fetal toxic effects. Lancet. 2001; 357: 363
|
|
|
|
|
|
4) 嶋田恵子, 他. カンデサルタンの母胎投与との関連が疑われた肺低形成, 腎不全を呈した早産児の1例. 日本新生児学会雑誌. 2001; 37: 398
|
|
|
|
|
5) 横田卓也, 他. カンデサルタン(アンジオテンシンII受容体拮抗薬)により新生児急性腎不全を発症した1例. 日本産婦人科学会雑誌. 2003; 55: 536
|
|
|
|
|
|
6) 喜多村薫, 他. アンジオテンシンII受容体拮抗薬の関与が疑われた羊水過少, 肺低形成の一例. 日本新生児学会雑誌. 2005; 41: 337
|
|
|
|
|
|
7) Hilgers KF, et al. Angiotensin's role in renal development. Semin Nephrol. 1997; 17: 492-501
|
|
|
|
|
|
8) Guron G. Renal haemodynamics and function in weanling rats treated with enalapril from birth. Clin Exper Pharm Pgysiol. 2005; 32: 865-70
|
|
|
|
|
|
9) Miyazakai Y, et al. The renal lesion that develop in neonatal mice during angiotensin inhibition mimic obstructive nephropathy. Kidney Int. 1999; 55: 1683-95
|
|
|
|
|
10) Lasaitiene D, et al. Neonatal RAS inhibition changes the phenotype of the developing thick ascending limb of Henle. Am J Physiol Renal Physiol. 2004; 286: 1144-53
|
|
|
|
|
|
11) Akil I, et al. Histopathological and ultrastructural effects of losartan on embryonic rat kidney. Acta Histochemica. 2005; 107: 291-300
|
|
|
|
|
|
12) Shotan A, et al. Risks of angiotensin-converting enzyme inhibition during pregnancy: Experi-mental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med. 1994; 96: 451-6
|
|
|
|
|
|
13) Saji H, et al. Losartan and fetal toxic effects. Lanset. 2001; 357: 363
|
|
|
|
|
|
14) Daikha-Bahmane F, et al. Foetal kidney maldevelopnent in maternal use of angiotensin II type I receptor antagonists. Pediatr Nephrol. 2006; 21: 729-32
|
|
|
|
|
|
15) Bhatt-Mehta V, et al. Fetal exposure to lisinopril: neonatal manifestations and management. Pharmacotherapy. 1993; 13: 515-8
|
|
|
|
|
|
16) Lenoir RM, et al. Fetal and neonatal effects of maternal treatment with angiotensin converting enzyme inhibitor. Arch Pediatr. 1994; 1: 497-500
|
|
|
|
|
|
17) Schaefer C. Angiotensin II-receprtor antagonists: Further evidence of fetotoxicity but not terato-genicity. Birth Defects Res. 2003; 67: 591-4
|
|
|
|
|
|
18) Pryde PG. Angiotensin-converting enzyme inhibitor fetopathy. J Am Soc Nephrol. 1993; 16: 1575-82
|
|
|
|
|
|
19) Tebbs C, et al. Angiotensin II is a growth factor in the peri-implantation rat embryo. J Anat. 1999; 195: 75-86
|
|
|
|
|
|
20) 日本腎臓学会｢腎疾患患者の妊娠に関するガイドライン作成小委員会｣. 腎疾患の妊娠に関する診療の手引き. 平成17年11月修正版
|
|
|
|
|